Cargando…

Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries

BACKGROUND: The preoperative selection of patients with lung cancer recurrence remains a major clinical challenge. Several aspects of this kind of surgery are still insufficiently evidence-based, with only a few series with more than 50 patients. METHODS: A retrospective study on 29 patients who und...

Descripción completa

Detalles Bibliográficos
Autores principales: Subotic, Dragan, Molins, Laureano, Soldatovic, Ivan, Moskovljevic, Dejan, Collado, Lucia, Hernández, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971423/
https://www.ncbi.nlm.nih.gov/pubmed/29807542
http://dx.doi.org/10.1186/s12957-018-1398-2
_version_ 1783326286194671616
author Subotic, Dragan
Molins, Laureano
Soldatovic, Ivan
Moskovljevic, Dejan
Collado, Lucia
Hernández, Jorge
author_facet Subotic, Dragan
Molins, Laureano
Soldatovic, Ivan
Moskovljevic, Dejan
Collado, Lucia
Hernández, Jorge
author_sort Subotic, Dragan
collection PubMed
description BACKGROUND: The preoperative selection of patients with lung cancer recurrence remains a major clinical challenge. Several aspects of this kind of surgery are still insufficiently evidence-based, with only a few series with more than 50 patients. METHODS: A retrospective study on 29 patients who underwent a completion pneumonectomy for postoperative lung cancer recurrence or new primary was done in the period between October 2004 and December 2015. Inclusion criteria include complete (R0) first and second resections, histologically proven recurrent or new malignancy, complete pathohistological report after both operations, and exact data about the treatment outcome at the time of the last contact with patients or their families. RESULTS: There were 25 (86.2%) males and 4 (13.8%) females (M:F 6.2:1). In 13/29 patients, the interval between the first and second operations was less than 2 years, while in the remaining 16 patients, it was longer than 2 years. Concerning the operative stage distribution, stage I was more frequent after the first operation (44.8 vs. 22%), while stage III was dominant after the second operation (40.7 vs. 10.3%). The same tumor histology after the first and second operations existed in 24 (82.8%) patients. Adjuvant treatment was given to 53.6% of patients after the first and to 45.5% of patients after the second operation. The overall 5-year survival was 30%, median survival being 35 ± 16.9 months (1.896, 68.104 95% CI). A median survival of patients in post-surgery stage I after re-do surgery was better in comparison with that in higher stages (35 ± 22.6 vs.17.2 ± 15.1 vs. 21 ± 6.7 months, p > 0.05). Patients with the same tumor type at both operations lived significantly longer (median survival 48 ± 21.5 vs. 7.7 ± 1.9 months) than patients with different tumor histology after the second operation. Patients under 60 years (42.9%) lived longer than patients older than 60 years (median survival 69 ± 4.5 vs. 17.2 ± 14.3 months). The Cox regression analysis revealed only the disease stage at first operation and the same/different tumor histology as significant prognostic factors. One patient died from cardiac insufficiency caused by bronchopleural fistula (3.4% operative mortality). Operative morbidity was 34.4%. CONCLUSION: Completion pneumonectomy may be a reasonable option for postoperative lung cancer recurrence or new primaries only in carefully selected patients, in whom the potential oncological benefits overweigh the surgical risk.
format Online
Article
Text
id pubmed-5971423
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59714232018-05-30 Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries Subotic, Dragan Molins, Laureano Soldatovic, Ivan Moskovljevic, Dejan Collado, Lucia Hernández, Jorge World J Surg Oncol Research BACKGROUND: The preoperative selection of patients with lung cancer recurrence remains a major clinical challenge. Several aspects of this kind of surgery are still insufficiently evidence-based, with only a few series with more than 50 patients. METHODS: A retrospective study on 29 patients who underwent a completion pneumonectomy for postoperative lung cancer recurrence or new primary was done in the period between October 2004 and December 2015. Inclusion criteria include complete (R0) first and second resections, histologically proven recurrent or new malignancy, complete pathohistological report after both operations, and exact data about the treatment outcome at the time of the last contact with patients or their families. RESULTS: There were 25 (86.2%) males and 4 (13.8%) females (M:F 6.2:1). In 13/29 patients, the interval between the first and second operations was less than 2 years, while in the remaining 16 patients, it was longer than 2 years. Concerning the operative stage distribution, stage I was more frequent after the first operation (44.8 vs. 22%), while stage III was dominant after the second operation (40.7 vs. 10.3%). The same tumor histology after the first and second operations existed in 24 (82.8%) patients. Adjuvant treatment was given to 53.6% of patients after the first and to 45.5% of patients after the second operation. The overall 5-year survival was 30%, median survival being 35 ± 16.9 months (1.896, 68.104 95% CI). A median survival of patients in post-surgery stage I after re-do surgery was better in comparison with that in higher stages (35 ± 22.6 vs.17.2 ± 15.1 vs. 21 ± 6.7 months, p > 0.05). Patients with the same tumor type at both operations lived significantly longer (median survival 48 ± 21.5 vs. 7.7 ± 1.9 months) than patients with different tumor histology after the second operation. Patients under 60 years (42.9%) lived longer than patients older than 60 years (median survival 69 ± 4.5 vs. 17.2 ± 14.3 months). The Cox regression analysis revealed only the disease stage at first operation and the same/different tumor histology as significant prognostic factors. One patient died from cardiac insufficiency caused by bronchopleural fistula (3.4% operative mortality). Operative morbidity was 34.4%. CONCLUSION: Completion pneumonectomy may be a reasonable option for postoperative lung cancer recurrence or new primaries only in carefully selected patients, in whom the potential oncological benefits overweigh the surgical risk. BioMed Central 2018-05-28 /pmc/articles/PMC5971423/ /pubmed/29807542 http://dx.doi.org/10.1186/s12957-018-1398-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Subotic, Dragan
Molins, Laureano
Soldatovic, Ivan
Moskovljevic, Dejan
Collado, Lucia
Hernández, Jorge
Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
title Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
title_full Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
title_fullStr Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
title_full_unstemmed Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
title_short Completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
title_sort completion pneumonectomy: a valuable option for lung cancer recurrence or new primaries
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971423/
https://www.ncbi.nlm.nih.gov/pubmed/29807542
http://dx.doi.org/10.1186/s12957-018-1398-2
work_keys_str_mv AT suboticdragan completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries
AT molinslaureano completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries
AT soldatovicivan completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries
AT moskovljevicdejan completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries
AT colladolucia completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries
AT hernandezjorge completionpneumonectomyavaluableoptionforlungcancerrecurrenceornewprimaries